About the Authors

Rufayda Mruwat

Affiliation Department of Biochemistry, Hebrew University Medical School, Jerusalem, Israel

Saul Yedgar

yedgar@md.huji.ac.il

Affiliation Department of Biochemistry, Hebrew University Medical School, Jerusalem, Israel

Iris Lavon

Affiliation Department of Neurology, Hadassah University Hospital, Jerusalem, Israel

Amiram Ariel

Affiliation Department of Biology, Faculty of Natural Sciences, University of Haifa, Haifa, Israel

Miron Krimsky

Affiliations Department of Neurology, Hadassah University Hospital, Jerusalem, Israel, Pediatric Department, Hadassah University Hospital, Jerusalem, Israel

David Shoseyov

Affiliation Pediatric Department, Hadassah University Hospital, Jerusalem, Israel

Competing Interests

The study used a compound (PLA2 inhibitor) proprietary of Celsus Therapeutics Plc. S. Yedgar serves on the board of the company and has shares in it. All other authors have no competing interests. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: RM SY IL AA MK DS. Performed the experiments: RM MK DS. Analyzed the data: RM SY IL AA DS. Contributed reagents/materials/analysis tools: IL AA MK DS. Wrote the paper: RM SY DS.